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Introduction
Many autoimmune diseases, including multiple sclerosis (MS), are 
driven by self-reactive T helper cells that promote autoimmune 
tissue inflammation, particularly after differentiation into Th1 or 
Th17 subsets (1). In order to maintain peripheral and tissue toler-
ance, self-reactive T effector cells that escape negative selection in 
the thymus are actively controlled in the periphery by a number of 
mechanisms, including expression of inhibitory cell surface recep-
tors. Cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed 
death-1 (PD-1), T cell immunoreceptor with immunoglobulin and 
ITIM domains (TIGIT), and T cell immunoglobulin- and mucin 
domain–containing molecule 3 (TIM-3) (2) are essential for con-
trolling autoreactive T cells, as loss of these inhibitory receptors 
results in hyperproliferation of effector T cells, induction of spon-
taneous inflammation, and severe autoimmunity. Consistent with 
this, the CTLA4 and PD1 genes have been identified as MS sus-
ceptibility loci (2), as defects in or dysregulation of inhibitory path-
ways allow self-reactive T cell responses to go unabated.
Therapeutic approaches using the inhibitory effects of 
these receptors are under active investigation and have already 
yielded remarkable results in the field of cancer immunotherapy, 
in which blockade of inhibitory pathways significantly improved 
antitumor T cell responses (3). Interestingly, combined blockade 
of TIM-3 and PD-1 in mouse tumor models appears to be even 
more potent in promoting antitumor immune responses (4), 
suggesting that targeting multiple inhibitory receptors may pro-
vide therapeutic synergy. Analogously, dampening self-reactive 
T cell responses in autoimmunity by modulation of inhibitory 
receptor function represents an exciting area for therapeutic 
development. Thus, the identification of additional inhibitory 
molecules may be of great value. In particular, since autoreac-
tive Th17 cells cause severe inflammation and irreversible tissue 
damage, molecules that preferentially modulate Th17 cell func-
tion are especially promising targets for controlling tissue injury 
in autoimmune disease.
Using gene expression profiling, we discovered that podo-
planin (PDPN), a 43-kDa transmembrane sialomucin-like gly-
coprotein, is preferentially expressed on the surface of in vitro–
differentiated Th17 cells but not on other effector T cell subsets 
(5). Moreover, during the development of experimental autoim-
mune encephalomyelitis (EAE) in vivo, PDPN is expressed on the 
surface of Th17 cells that infiltrate the target tissue. We further 
showed that blockade of PDPN inhibits formation of ectopic lym-
phoid follicles (eLFs) in the CNS induced by adoptive transfer of 
myelin oligodendrocyte glycoprotein–specific (MOG-specific) 
Th17 cells (5). However, because PDPN is also expressed on many 
other cell types, including lymphatic endothelial cells, fibroblas-
tic reticular cells, follicular dendritic cells, and subsets of macro-
phages (6, 7), the functional role of PDPN specifically on T cells 
has not been elucidated.
Podoplanin (PDPN, also known as Gp38) is highly expressed on the surface of lymphatic endothelial cells, where it 
regulates development of lymphatic vessels. We have recently observed that PDPN is also expressed on effector T cells 
that infiltrate target tissues during autoimmune inflammation; however, the function of PDPN in T cells is largely unclear. 
Here, we demonstrated that global deletion of Pdpn results in exaggerated T cell responses and spontaneous experimental 
autoimmune encephalomyelitis (EAE) in mice with a susceptible genetic background. In contrast, T cell–specific 
overexpression of PDPN resulted in profound defects in IL-7–mediated T cell expansion and survival. Consequently, these 
animals exhibited a more rapid resolution of CNS inflammation, characterized by a reduced effector CD4+ T cell population 
in the CNS. Mice harboring a T cell–specific deletion of Pdpn developed exacerbated EAE, with increased accumulation of 
effector CD4+ T cells in the CNS. Transcriptional profiling of naturally occurring PDPN+ effector T cells in the CNS revealed 
increased expression of other inhibitory receptors, such as Pd1 and Tim3, and decreased expression of prosurvival factors, 
including Il7ra. Together, our data suggest that PDPN functions as an inhibitory molecule on T cells, thereby promoting tissue 
tolerance by limiting long-term survival and maintenance of CD4+ effector T cells in target organs.
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spared (Figure 1A and Supplemental Table 1). A more detailed 
histological analysis of the intestine showed that the number of 
infiltrates, in particular those of medium and large size, was sig-
nificantly increased in PDPN-deficient mice (Figure 1, A and B). 
The phenotype of Pdpn–/– mice thus bears resemblance to what 
has been observed in mice lacking molecules that inhibit T cell 
responses, such as CTLA-4– or PD-1–deficient mice (10, 11), and 
prompted us to further characterize the cells spontaneously infil-
trating the lungs and livers of Pdpn–/– mice. As expected, the total 
number of cells isolated from lungs and livers was significantly 
higher in PDPN-deficient mice compared with that in Pdpn+/– or 
Pdpn+/+ littermates (Supplemental Figure 1). The cellular compo-
sition of the infiltrates in lungs and livers of PDPN-deficient mice 
was highly variable, as they contained differing frequencies of B 
cells, macrophages, and dendritic cells. However, we consistently 
detected substantial T cell infiltration in organs from PDPN-defi-
cient mice by immunohistochemistry (Figure 1A). To analyze the 
effect of PDPN deficiency more specifically on T cells, we sorted 
naive T cells (CD4+CD62Lhi) from Pdpn knockout (PdpnKO) mice 
and their WT littermates and measured expansion in response 
to anti-CD3. Importantly, PdpnKO T cells expanded significantly 
more than WT T cells, suggesting that lack of PDPN promotes a 
hyperproliferative T cell phenotype (Figure 1C).
Next, we crossed PDPN-deficient mice to 2D2 mice, which 
bear a transgenic T cell receptor specific for MOG (12). Importantly, 
all 2D2 Pdpn–/– mice developed spontaneous EAE at around the age 
of 6 weeks, with a mean maximum score of 2.6 ± 0.2, whereas the 
2D2 Pdpn+/– littermates remained free of clinical signs of disease 
(Table 1). Consistent with the clinical data, histological analysis 
of the CNS showed that 2D2 Pdpn–/– mice had demyelination and 
inflammatory lesions in meninges and parenchyma, whereas no 
lesions were found in the CNS of 2D2 Pdpn+/– littermates (Table 1). 
To further investigate the role and function of PDPN on CD4 
T cells during CNS inflammation, we have analyzed the effects 
of both loss and overexpression of PDPN on T cell responses 
using global PDPN-deficient mice, T cell–specific Pdpn trans-
genic mice, and T cell–specific PDPN-deficient mice. Our results 
demonstrate that PDPN acts as an inhibitory molecule on T cells 
by limiting survival and maintenance of CD4 effector T cells in 
target tissues. As PDPN is primarily expressed on T cells infiltrat-
ing such tissues, our results suggest that one important function 
of PDPN on T cells is to inhibit their survival in the target tissues 
and thus promote tissue tolerance.
Results
PDPN-deficient mice have enhanced T cell responses. To study the 
role of PDPN in T cell biology, we characterized the T cell pheno-
type of PDPN-deficient mice. Although Pdpn–/– mice on the 129Sv 
genetic background suffer from defects in heart and lung develop-
ment and die shortly after birth due to respiratory failure (8, 9), we 
previously described that PDPN-deficient mice can survive on a 
mixed 129Sv × C57BL/6 background and reach adulthood, albeit 
with very low frequency (5). In the few surviving mice, we consis-
tently observed exaggerated immune responses. As we have shown 
previously, PDPN-deficient mice have a defect in forming nor-
mally structured peripheral lymph nodes and thus do not develop 
lymphadenopathy. However, PDPN-deficient mice consistently 
developed moderate splenomegaly, while thymic cell numbers 
were normal (Supplemental Figure 1; supplemental material avail-
able online with this article; doi:10.1172/JCI74685DS1). Along 
with splenomegaly, we also found increased lymphocytic infil-
trates in several organs in PDPN-deficient mice when compared 
with Pdpn+/– or Pdpn+/+ littermates. Affected organs included lung, 
liver, and large and small intestine, whereas heart and CNS were 
Figure 1. PDPN-deficient mice show exaggerated 
T cell responses. (A) Lungs and intestines were 
harvested from PDPN-deficient mice and their 
WT littermates. Sections of the formalin-fixed 
and paraffin-embedded tissues were stained with 
hematoxylin and eosin. Both Pdpn–/– lung and small 
intestine show lymphocytic infiltrates (dark blue, 
arrows). Sections of lung and intestine were also 
analyzed for the presence of T cells (CD3, dark brown) 
by immunohistochemistry (right panels). Scale bar: 
50 μm. For more information refer to Supplemental 
Table 1. (B) The number of small, medium, and large 
infiltrates in the small intestines of PDPN-deficient 
mice (n = 4) and their WT or heterozygous litter-
mates (n = 4) was quantified. (C) Sorted naive T cells 
from PDPN-deficient mice and their WT littermates 
were stimulated in vitro with different concen-
trations of anti-CD3 in the presence of irradiated 
APCs for 72 hours. Proliferation was measured by 
thymidine incorporation in the last 18 hours. Data 
shown are representative of 3 or more independent 
experiments. *P < 0.05, **P < 0.01, ***P < 0.001.
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CD2 promoter (referred to herein as PdpnTG mice [also known as 
Tg(Cd2-Pdpn) mice]) (Supplemental Figure 2). We obtained 3 dif-
ferent PdpnTG founder lines with different levels of Pdpn expres-
sion. All 3 lines were viable and fertile, had normal life expectan-
cies, and did not show any obvious developmental abnormalities. 
Importantly, we saw no evidence of increased PDPN expression 
in CD19+ B cells or CD11b/CD11c+ myeloid cells isolated from the 
secondary lymphoid organs of PdpnTG mice (Supplemental Figure 
3A). Additionally, overexpression of PDPN in the T cell compart-
ment did not alter the relative frequency of lymph node stromal cell 
populations (Supplemental Figure 3B), supporting that selective 
overexpression only occurs in T cells. Analysis of PDPN expres-
sion levels on peripheral T cells revealed that founder line 552 was 
a low expressor, i.e., 5%–10% of the CD4 T cells and 3%–8% of 
the CD8 T cells isolated from lymph nodes or spleens expressed 
PDPN (Figure 2A and Supplemental Figure 3, C and D). In con-
trast, founder line 560 was a high expressor, with the majority 
(50%–80%) of peripheral CD4 T cells expressing PDPN. The frac-
tion of PDPN-positive CD8 T cells in the high expressor lines was 
These data further indicate that global lack of PDPN leads to a 
hyperactive T cell phenotype in vivo and spontaneous T cell–medi-
ated autoimmune disease on a susceptible background.
Overexpression of PDPN causes severe peripheral T cell lymphope-
nia. Based on our observations, the spontaneous exaggerated T cell 
responses in PDPN-deficient mice may be due to the lack of PDPN 
on T cells themselves. However, aside from T cells, PDPN is also 
expressed on other cell types, including, for example, subsets of 
macrophages, follicular dendritic cells, fibroblastic reticular cells, 
and lymphatic endothelial cells. Thus, the analysis and interpreta-
tion of data from globally PDPN-deficient mice is complicated by 
the fact that lack of PDPN on other cell types may also modulate T 
cell responses. Moreover, the extremely poor survival of PDPN-defi-
cient mice combined with their mixed genetic background resulted 
in high experimental variability and made a more detailed analysis 
of the T cell phenotype of globally PDPN-deficient mice unfeasible.
To overcome these hurdles and to study the role of PDPN in 
T cell biology more specifically, we generated T cell–specific Pdpn 
transgenic mice that express Pdpn under the control of the human 
Table 1. 2D2 PdpnKO mice develop spontaneous EAE
Mice Incidence of EAE Age at onset (wk) Mean max. score No. of meningeal lesions No. of parenchymal lesions No. of total lesions
2D2 Pdpn+/– 0/6 N/A N/A 1 ± 1 0 ± 0 1 ± 1
2D2 Pdpn–/– 4/4 6.4 ± 0.2 2.6 ± 0.3 82 ± 7 85 ± 20 167 ± 21
max., maximum; N/A, nonapplicable.
Figure 2. PDPN T cell transgenic mice develop severe 
peripheral lymphopenia. (A) Lymph nodes were 
harvested from 2 independent lines of 6- to 12-week-
old PdpnTG mice and their WT littermates. CD4 T 
cells were analyzed for expression of PDPN by flow 
cytometry. Numbers represent the percentage of CD4 T 
cells. (B) Thymuses were harvested from 2 independent 
lines of 6- to 12-week-old PdpnTG mice and their WT 
littermates and analyzed for the presence of CD8+ and 
CD4+ T cell populations by flow cytometry. Numbers 
represent the percentage of total thymocytes. Data 
are representative of >5 mice of each group. (C) Total 
lymph node cells from 2 lines of PdpnTG mice and their 
WT littermates were analyzed for the presence and 
percentage of CD4 T cells. Data points represent indi-
vidual mice (n = 4 or more). Horizontal bars indicate the 
mean. (D) The total number of CD8 and CD4 T cells as 
well as CD19 B cells in the spleens of 2 lines of PdpnTG 
mice and their WT littermates was determined by flow 
cytometry. All data are representative of at least 3 
independent experiments. ***P < 0.001.
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almost 10-fold reduced in the high expressor line, whereas the 
low expressor line had similar frequency and numbers of T cells 
as WT mice (Figure 2, C and D, and Supplemental Figure 5A). We 
observed similar degrees of T cell lymphopenia in the high expres-
sor line in spleens and lymph nodes, both in terms of total T cell 
numbers and percentage of T cells among total live cells. In con-
trast to CD4 and CD8 T cells, γ/δ T cell numbers were relatively 
normal in PdpnTG high expressor mice (Supplemental Figure 5B). 
Similarly, normal numbers of non–T cell populations, including B 
cells, macrophages, and dendritic cells, were present in spleens 
and lymph nodes of the PdpnTG high expressor line, although the 
percentage of B cells and CD11b/c+ cells was increased as a con-
sequence of the reduced T cell populations (Figure 2D and Sup-
plemental Figure 5B).
much smaller and more variable (2%–20% in line 560)(Figure 2A 
and Supplemental Figure 3, C and D). The third founder line (line 
556) largely recapitulated the phenotype of the high expressor line 
560 and therefore was not included here.
To assess whether overexpression of PDPN affects T cell 
development, we analyzed the different T cell populations in 
the thymus. We found normal frequencies and total numbers of 
double-positive, CD4 single-positive, CD8 single-positive, and 
double-negative thymocytes in all PdpnTG lines (Figure 2B and 
Supplemental Figure 4). These data suggest that thymic T cell 
development is unperturbed in PdpnTG mice.
We next analyzed T cell populations in the spleens and 
lymph nodes of the transgenic mice. Importantly, we found that 
frequency and total number of both CD4 and CD8 T cells were 
Figure 3. Overexpression of PDPN limits IL-7–dependent T cell survival. (A) Splenocytes from WT and PdpnTG mice (line 560) were analyzed for expres-
sion of CD44, PDPN, and IL-7Rα on CD4+FOXP3/GFP– T effector cells (Teff) by flow cytometry. Numbers represent the percentage of CD4 T cells. (B) RNA 
was isolated from CD4+Foxp3.GFP–CD44hi and CD4+Foxp3.GFP–CD44lo T cells sorted from spleens and lymph nodes of naive WT and PdpnTG mice (line 560). 
Expression of PDPN and IL-7Rα was assessed by quantitative PCR. (C, D, and F) CD4 T cells were purified from Ly5.1 WT and Ly5.2 PdpnTG mice (line 560) 
and mixed. (C) Cells were cultured in vitro with the indicated concentrations of IL-7, and the percentage of 7AAD– cells at different time points was deter-
mined by flow cytometry. (D) Cells were cultured in vitro in the presence of IL-2 (1 ng/ml), IL-7 (1 ng/ml), or IL-15 (10 ng/ml). The ratio of surviving Ly5.1+ WT 
to Ly5.2+ PdpnTG CD4 T cells after 96 hours was determined by flow cytometry. Data points represent independent replicates. (E) CD4+CD25– T cells sorted 
from WT and PdpnTG mice (line 560) were cultured in vitro in the presence or absence of anti-CD3. The expression of IL-7Rα on T cells was determined by 
flow cytometry at the indicated time points. (F) Mixed Ly5.1+ WT and Ly5.2+ PdpnTG (line 560) CD4 T cells were adoptively transferred into CD90.1+ recipi-
ents. Twenty-one days after transfer, the frequency of Ly5.1+ WT and Ly5.2+PdpnTG cells among CD90.2+CD4+ cells was determined in the indicated organs. 
Data shown are representative of at least 2 independent experiments. *P < 0.05, ***P < 0.0001.
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that in PdpnTG mice the naive CD44lo CD4 T cells expressed very 
high amounts of PDPN but reduced levels of IL-7Rα compared 
with naive CD44lo CD4 T cells from WT mice. In contrast, mem-
ory CD44hi CD4 T cells from PdpnTG mice, which expressed less 
PDPN than naive PdpnTG CD4 T cells both in terms of percentage 
and level of expression as determined by MFI, had similar amounts 
of IL-7Rα compared with memory T cells from WT mice (Figure 
3A). Consistent with the protein data, we also found reduced Il7ra 
mRNA levels in naive CD4 effector T cells from PdpnTG mice 
compared with naive CD4 effector T cells from WT mice, whereas 
Il7ra mRNA levels were comparable between PdpnTG and WT 
memory T cells (Figure 3B). These data suggest that expression of 
PDPN and IL-7Rα are inversely correlated in PdpnTG CD4 T cells.
Since PDPN expression was higher and IL-7Rα expression was 
lower on PdpnTG naive T cells compared with PdpnTG memory T 
cells, we next determined the frequencies of naive, memory, and 
Given that only the high expressor PdpnTG mice developed 
peripheral T cell lymphopenia, while low expressor PdpnTG mice 
had normal T cell numbers, these data suggest that expression of 
high levels of PDPN on T cells leads to impaired survival and/or 
proliferation and interferes with normal T cell homeostasis.
PdpnTG T cells have a defect in IL-7–mediated survival. After 
exiting the thymus, T cells circulating through peripheral lym-
phoid organs depend on survival cues for their maintenance and 
expansion. One of the most important survival signals is provided 
by the cytokine IL-7, which is mainly produced by the stromal cells 
of secondary lymphoid organs, and defects in IL-7/IL-7Rα signal-
ing have been shown to cause severe lymphopenia (13). To deter-
mine whether the lymphopenia in our PdpnTG high expressor line 
could be associated with defective IL-7 signaling, we first analyzed 
FOXP3– CD4 T effector cells from WT and PdpnTG mice (line 
560) for expression of IL-7Rα and PDPN. Interestingly, we found 
Figure 4. PdpnTG mice recover better from 
EAE. (A and B) PdpnTG mice (line 552) and 
their WT littermates were immunized with 
MOG/CFA and (A) monitored for clinical signs 
of EAE for 30 days. Linear regression analysis 
for the onset phase (day 7–14) as well as the 
recovery phase (day 14–30) of disease is also 
shown. For the onset phase no significant 
difference was detected, whereas PdpnTG 
mice recovered significantly better than WT 
mice (P = 0.0045). Data are representative of 
at least 4 mice per group and 3 independent 
experiments. (B) Graphs show time of onset, 
mean maximum score, and time with a score 
of 3 or higher for WT mice and PdpnTG mice 
(line 552). For more information also refer to 
Table 2. (C) Mononuclear cells were isolated 
from the CNS of WT and PdpnTG mice (line 
552) at the peak of disease and analyzed 
for expression of PDPN and FOXP3 by flow 
cytometry. Plots show live CD4+CD11b– T 
cells only and are representative of more 
than 3 independent experiments. Numbers 
represent the percentage of CD4 T cells. (D) 
Mononuclear cells were isolated from the 
CNS of WT and PdpnTG mice (line 552) at 
the peak of disease and counted. Cells were 
analyzed for expression of FOXP3, IL-17A, 
IFN-γ, and IL-10 by flow cytometry. Data 
points represent individual mice. Horizontal 
bars indicate the mean.
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Tregs among the remaining CD4 T cells in PdpnTG mice. Impor-
tantly, the frequency of naive T cells was greatly reduced in high 
expressor PdpnTG mice, whereas frequencies of both activated/
memory phenotype T cells and FOXP3+ Tregs were increased 
(Supplemental Figure 6). Although it is important to note that all 
T cell populations were reduced in total numbers in high expres-
sor PdpnTG mice (Supplemental Figure 6), these data imply that 
PDPN overexpression has a greater affect on naive T cells than on 
activated/memory T cells and Tregs.
We have shown that expression of PDPN and IL-7Rα is 
inversely correlated in PdpnTG T cells. To test whether PdpnTG 
CD4 T cells have a defect in IL-7–mediated survival, we cocultured 
unactivated congenic WT and PdpnTG CD4 T cells (high expressor 
line 560) in the presence of exogenous IL-7 and monitored their 
survival. At high concentrations of IL-7, WT and PdpnTG CD4 T 
cells survived equally well. However, at low concentrations of IL-7, 
WT CD4 T cells survived much better than PdpnTG CD4 T cells 
(Figure 3C). We next assessed whether PdpnTG CD4 T cells also 
demonstrated impaired survival in response to other γc-dependent 
cytokines. While coculture of WT and PdpnTG CD4 T cells with 
IL-7 resulted in preferential survival of WT CD4 T cells, this was 
not seen with either IL-2 or IL-15, indicating that PdpnTG CD4 
T cells are specifically impaired in their ability to respond to and 
compete for IL-7 (Figure 3D).
IL-7 signals are essential for slow homeostatic expansion and 
survival of T cells in the periphery. However, upon antigen encoun-
ter and during the ensuing activation phase, CD4 effector T cells 
rely primarily on TCR stimulation, IL-2, and inflammatory cyto-
kines for proliferation signals rather than IL-7 and thus downreg-
ulate expression of IL-7Rα during activation/effector phases of the 
adaptive immune response. When effector CD4 T cell populations 
contract after an acute immune response, expression of IL-7Rα 
is recovered to permit long-term survival of memory-precursor 
CD4 T cells (14). To determine the kinetics of IL-7Rα expression 
on PdpnTG T cells during and after activation, we stimulated WT 
and PdpnTG CD4 T cells with anti-CD3 and followed the expres-
sion of IL-7R over time. As expected, 12 hours after activation with 
anti-CD3, WT CD4 T cells had completely downregulated IL-7Rα 
compared with cells that were not stimulated with anti-CD3. Over 
time WT CD4 T cells then slowly regained cell surface expression 
of IL-7Rα and reached levels comparable to those of unstimulated 
cells at 96 hours (Figure 3E). In contrast, PdpnTG T cells were not 
able to recover expression of IL-7Rα nearly as well as WT T cells. 
Strikingly, among the PdpnTG CD4 T cells, PDPNhi cells had the 
biggest defect in regaining IL-7Rα expression, whereas PDPNlo 
cells managed to at least partially restore IL-7Rα expression on the 
surface, albeit not to WT levels (Figure 3E). These data suggest that 
PDPN+ CD4 T cells may exhibit impaired survival due to a defect 
in IL-7Rα expression. To determine whether PdpnTG CD4 T cells 
also show impaired survival in vivo, CD4 T cells from Ly5.2+Thy1.2+ 
PdpnTG mice were mixed with Ly5.1+Thy1.2+ WT cells (~60% WT, 
~40% transgenic), and adoptively transferred into Thy1.1+ mice. 
After 3 weeks, over 90% of all transferred Thy1.2+ CD4+ cells in the 
spleens, lymph nodes, and mesenteric lymph nodes were Ly5.1+ 
WT cells, while very few Ly5.2+ PdpnTG cells were detected. This 
experiment demonstrates that overexpression of PDPN in CD4 T 
cells also impairs their survival in vivo (Figure 3F).
To gain additional insight into the mechanism by which PDPN 
functions as an inhibitory molecule on T cells, we obtained mice 
deficient for CLEC-2, a C-type lectin-like receptor that is a binding 
partner for PDPN (15). Similar to global Pdpn–/– mice, global Clec2–/– 
mice on the 129Sv background also exhibit very poor survival rates 
and have aberrant lymphatic development (16). Upon crossing 
Clec2–/– mice with the high expressor PdpnTG line, we observed an 
almost complete rescue of the lymphopenic phenotype, as Clec2–/– 
PdpnTG mice had normal numbers of peripheral T cells, whereas 
their Clec2+/– PdpnTG littermates showed severe T cell lymphope-
nia (Supplemental Figure 7A). In addition, Clec2–/– PdpnTG CD4 T 
cells expressed similar levels of IL-7Rα as Clec2–/– CD4 T cells, both 
in terms of protein and mRNA, while Clec2+/– PdpnTG CD4 T cells 
showed strong downregulation of IL-7Rα compared with Clec2+/– 
controls (Supplemental Figure 7, B and C). These data suggest that 
the severe T cell lymphopenia and downregulation of IL-7Rα in 
PdpnTG mice is mediated by a PDPN-CLEC2 interaction.
PdpnTG mice recover better from EAE. We have shown that 
overexpression of PDPN on CD4 T effector cells impairs their 
ability to recover expression of IL-7Rα after T cell activation. This 
supports the hypothesis that, after the acute activation phase of an 
immune response is over, PDPN+ T cells may not be able to survive 
due to their impaired ability to respond to IL-7 signals, and thus 
expression of PDPN on T cells may serve to limit excessive tissue 
inflammation. To test this hypothesis during CNS inflammation in 
EAE, we used the low expressor PdpnTG mice (line 552), because 
these mice have similar numbers of T cells and similar frequencies 
of naive, memory, and Treg populations at baseline as WT mice. 
Upon immunization with MOG35–55 in CFA for induction of active 
EAE, WT and low expressor PdpnTG mice developed clinical signs 
of disease with similar kinetics and reached similar maximum 
scores, indicating that the acute activation phase of the immune 
response is comparable between WT and PdpnTG mice (Figure 4, 
A and B, and Table 2). However, consistent with our hypothesis, 
PdpnTG mice spent less time at their maximum score (Figure 4B 
Table 2. EAE in PdpnTG mice (line 552)
Mice Incidence  
of EAE
Mortality Day of onset Mean max.  
score
No. of days with  
score ≥3
No. of meningeal  
lesions
No. of parenchymal  
lesions
No. of total  
lesions
WT 11/14 0/14 9.9 ± 0.6 3.1 ± 0.1 6.4 ± 1.4 73 ± 17 90 ± 19 163 ± 34
PdpnTG 13/15 0/15 8.8 ± 0.3 2.7 ± 0.2 2.4 ± 0.8 15 ± 5 12 ± 5 27 ± 9
P values NS NS P = 0.0161 P = 0.0018 P = 0.0002 P = 0.0004
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and Table 2) and thus recovered better and more quickly than 
WT mice, as shown by linear regression analysis of the recovery 
phase (Figure 4A). The improved recovery was also reflected in 
the histological analysis of the CNS, as we observed fewer lesions 
in the CNS of PdpnTG mice compared with their WT counterparts 
(Table 2). To determine the cellular basis of the improved recovery 
we analyzed the CNS-infiltrating cells. We first analyzed expres-
sion of PDPN on CD4 T cells infiltrating the CNS at the peak of 
disease. Importantly, PDPN expression was consistently higher 
on both effector and Tregs in the CNS of PdpnTG mice compared 
with WT mice (Figure 4C), confirming that under acute inflamma-
tory conditions even the low expressor line of PdpnTG mice serves 
as a good model for PDPN overexpression. Upon isolation of 
CNS-infiltrating cells at the peak of disease, we found that, despite 
similar clinical scores, the number of infiltrating cells was already 
significantly lower in PdpnTG mice compared with that in WT 
mice (Figure 4D). In addi-
tion, the frequencies of 
IL-10–producing CD4 T 
cells and FOXP3+ Tregs were 
significantly increased, while 
the frequencies of IL-17– 
and IFN-γ–producing CD4 
effector T cells were slightly 
decreased (Figure 4D). These 
data support the hypothesis 
that the improved recovery 
in PdpnTG mice may be due 
to impaired survival of T 
effector cells in the CNS: not 
only did we recover fewer 
total cells from the CNS of 
PdpnTG mice, but the fre-
quency of CD4 T effectors 
was also decreased in favor 
of an increase in FOXP3+ 
Tregs in PdpnTG mice. 
Together with an increase 
of IL-10 producers and a 
decrease of IL-17/IFN-γ pro-
ducers, this cellular environ-
ment promotes recovery and 
limits inflammation.
Selective deficiency of 
PDPN in T cells exacerbates 
EAE. In order to further 
investigate the T cell–specific 
role of PDPN, we used 
Pdpnfl/fl mice crossed to Cd4- 
Cre transgenic mice. Upon 
in vitro differentiation into 
Th17 cells, CD4 T cells from 
Pdpnfl/fl Cd4-Cre mice ex-
pressed no detectable PDPN, 
unlike cells from control 
Pdpnfl/fl mice, confirming 
con ditional deletion of Pdpn 
(Figure 5A). We next immunized Pdpnfl/fl Cd4-Cre mice or control 
Pdpnfl/fl mice with MOG35–55 in CFA to induce EAE. Notably, Pdpnfl/fl 
Cd4-Cre mice developed clinical signs of disease more rap-
idly and had significantly higher scores between days 10 and 14 
(P < 0.05) than did control Pdpnfl/fl mice (Figure 5B). Consistent with 
the more rapid onset and increased severity of disease in Pdpnfl/fl 
Cd4-Cre mice, we observed increased numbers of CNS-infiltrating 
cells, including CD4 T cells, in Pdpnfl/fl Cd4-Cre mice compared 
with Cre-negative controls (Figure 5C). To confirm that PDPN- 
deficient CD4 T cells preferentially accumulate in the CNS during 
EAE, we adoptively transferred CD4 T cells isolated from either 
Pdpnfl/fl Cd4-Cre or Pdpnfl/fl mice expressing the 2D2 TCR trans-
gene into naive mice and then immunized the recipients to induce 
EAE. We consistently observed a higher frequency of 2D2+ T cells 
(identified by the expression of Vβ11) in the CNS of mice that had 
received 2D2+ Pdpnfl/fl Cd4-Cre T cells (Figure 5D). Taken together, 
Figure 5. Selective deletion of PDPN in CD4+ T cells results in enhanced severity of EAE and increased CD4 T cell 
accumulation in the CNS. (A) CD4 T cells were isolated from Pdpnfl/fl Cd4-Cre+ or Cd4-Cre– controls and differentiated 
into Th17 cells. PDPN expression was assessed by flow cytometry. Data are representative of more than 4 independent 
experiments. Numbers represent the percentage of CD4 T cells. (B and C) Pdpnfl/fl Cd4-Cre+ or control Cd4-Cre– mice 
were immunized with MOG/CFA for the development of EAE. (B) Average clinical score over 30 days is shown. Data 
represent pooled data from 2 independent experiments (Pdpnfl/fl Cd4-Cre+, n = 12; Pdpnfl/fl Cd4-Cre–, n = 6). (C) Cells 
were isolated from the CNS of Pdpnfl/fl Cd4-Cre+ or control mice, and both the total number of infiltrating CD4 T cells 
as well as the number of infiltrating CD4 T cells was determined. Data points represent individual mice from 2 inde-
pendent experiments. (D) Naive CD4 T cells were isolated from 2D2+ Pdpnfl/fl Cd4-Cre+ or 2D2+ Pdpnfl/fl Cd4-Cre– mice 
and adoptively transferred into WT mice, which were then immunized with MOG/CFA for the development of EAE. 
Mononuclear cells were isolated from the CNS of mice at day 10 after immunization, and the frequency of transgenic 
Vβ11+CD4+ T cells was determined by flow cytometry. Each data point represents an individual mouse. Data are repre-
sentative for 2 independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001.
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In order to determine whether naturally occurring PDPN+ CD4 
T cells show features similar to PdpnTG T cells, we next compared 
gene expression profiles of PDPN+ and PDPN– effector CD4 T cells. 
Since naturally occurring PDPN+ CD4 T cells are primarily found in 
inflamed tissues, we immunized Foxp3.GFP reporter mice to induce 
development of EAE, isolated PDPN+ and PDPN–FOXP3– effector 
CD4 T cells from the CNS, and compared their gene expression 
profile with the multiplex NanoString nCounter technology using a 
custom-made code set of 199 genes. We were thus able to identify a 
set of genes that was consistently downregulated or upregulated in 
PDPN+ effector CD4 T cells in the CNS compared with PDPN– effec-
tor CD4 T cells in the CNS (Figure 6B and Supplemental Table 2). 
Interestingly, we found several factors associated with T cell inhibi-
tion to be upregulated in PDPN+ effector CD4 T cells, such as GRAIL, 
TIM-3, LAG3, PD-1, and CD39. Moreover, several prosurvival factors, 
including BCL2, FOXO1, and IL-7Rα, were downregulated in PDPN+ 
effector CD4 T cells in the CNS. These data indicate that PDPN+ T 
cells may be readily inhibited and more susceptible to apoptosis.
To validate the downregulation of prosurvival factors in 
PDPN+ CD4 T cells, we measured mRNA levels of Bcl2 and Il7ra 
in PDPN+ and PDPN– effector CD4 T cells isolated from the CNS 
these data show that CD4 T cell–specific deletion of PDPN results 
in increased accumulation of CD4 T cells in the CNS and conse-
quently leads to a more rapid onset and increased severity of EAE.
Natural PDPN+ T effector cells exhibit an inhibitory phenotype. 
We have shown that EAE overexpression of PDPN on T cells 
leads to reduced numbers of T effector cells in the CNS, resulting 
in accelerated recovery and protection of the tissue, while T cell–
specific deletion of PDPN leads to an exacerbated disease course 
characterized by increased numbers of T effector cells in the CNS. 
To explore whether natural PDPN expression on T cells has similar 
effects on T effector cell survival, we first analyzed the kinetics of 
PDPN expression on T cells during the development of an immune 
response. During the T cell activation/priming phase following 
immunization of WT mice, there was no significant expression 
of PDPN on T cells from either the lymph nodes or spleens (Fig-
ure 6A). Consistent with our previous findings (5), effector T cells 
isolated from the CNS during onset and early peak of EAE were 
largely PDPN positive. In contrast, the frequency of PDPN+ T effec-
tor cells isolated from the CNS during the recovery phase of EAE 
was reduced (Figure 6A), suggesting that PDPN+ T effector cells 
either disappear or downregulate PDPN during the recovery phase.
Figure 6. Natural PDPN+ T effector cells in 
the CNS show an inhibited phenotype. (A) 
WT mice were immunized with MOG/CFA 
for the development of EAE. Expression 
of PDPN on CD4 T cells isolated from 
spleens (SP) and lymph nodes 8 days after 
immunization and from the CNS either at 
the onset of disease or during recovery was 
determined by flow cytometry. Numbers 
represent the percentage of CD4 T cells. 
(B–D) Foxp3.GFP-KI mice were immunized 
with MOG/CFA for the development of 
EAE. At the peak of disease, infiltrating 
cells were isolated from the CNS and 
Foxp3.GFP–CD11b–CD4+PDPN+ and Foxp3.
GFP–CD11b–CD4+PDPN– T cells were isolated 
by FACS sorting. (B) mRNA gene expres-
sion profiles were generated from both 
populations using NanoString technology. 
Graphs show selected genes that were 
consistently downregulated or upregulated 
in PDPN+ T effectors compared with PDPN– 
T effectors in 3 independent experiments. 
(C) mRNA was isolated from both popula-
tions, and the expression patterns of Il7ra 
and Bcl2 were confirmed by quantitative 
PCR. Graphs shown are representative of 
2 independent experiments. (D) PDPN+ 
and PDPN– T effector cells isolated from 
the CNS were analyzed for expression of 
PD-1 and TIM-3 by flow cytometry, and the 
percentage of TIM-3+PD-1+ T cells among 
each group is shown. (E) WT CD4 T cells 
were stimulated with plate-bound anti-
CD3 and anti-CD28 Abs and differentiated 
in the presence of no cytokine (Th0), IL-6 
and TGF-β, or IL-1β, IL-6, and IL-23. After 4 
days, cultures were analyzed for expres-
sion of PDPN by flow cytometry. Data are 
representative of more than 3 indepen-
dent experiments.
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nals. On the one hand, IL-7 survival signals are essential for nor-
mal T cell homeostasis in naive mice. This explains why PdpnTG 
high expressors display severe peripheral lymphopenia, in which 
loss of naive T cells (which had the highest expression of PDPN on 
their surface) was more pronounced than loss of memory and Treg 
populations (Supplemental Figure 6).
On the other hand, IL-7 signals are not crucial during the T cell 
activation/acute phases of an immune response, but after acute 
activation signals fade, T cells recover IL-7Rα expression and rely 
on IL-7 signals once again for long-term maintenance of T effector 
cells. Consistent with our hypothesis that the inhibitory effects of 
PDPN are most evident in situations in which T cells require IL-7 
signals, our data suggest that, unlike CTLA-4, PD-1, or TIGIT, 
PDPN does not seem to directly interfere with TCR signaling or 
dampen T cell activation. This is supported by our observation that 
PdpnTG and WT mice have a similar EAE disease course during the 
initial phase in terms of disease incidence, onset, and maximum 
score (Figure 4) and by the fact that in vitro–generated Th17 cells 
have a very activated phenotype despite high levels of PDPN on 
their surface. In contrast, during active EAE, CTLA-4 T cell trans-
genic mice show reduced maximum disease severity (20), and 
many studies have shown that CTLA-4 and PD-1 directly inhibit 
T cell activation (2). The molecular basis for this difference most 
likely lies in the fact that PDPN does not have an immunoreceptor 
tyrosine-based inhibitory motif (ITIM) in its short cytoplasmic tail, 
which is required for CTLA-4, PD-1, and TIGIT to modulate TCR 
signaling (2). The inhibitory effects of PDPN become more appar-
ent and important in the later phases of disease, as indicated by the 
more rapid recovery associated with a reduced number of T effec-
tor cells in the CNS of PdpnTG mice (Figure 4), the increased num-
ber of T effector cells in the CNS of T cell–specific PdpnKO mice 
(Figure 5), and the disappearance of natural PDPN+ T effector cells 
in the CNS after the peak of disease (Figure 6A). Thus, PDPN may 
promote tissue tolerance by interfering with T effector cell survival 
and maintenance rather than initial activation or differentiation.
Aside from the inhibitory effects of PDPN expression on T 
cells, we have described previously that global PDPN expression 
also supports the formation of eLFs in the CNS induced by adoptive 
transfer of Th17 cells (5, 21). Therefore, the important question that 
arises is how PDPN can inhibit T cell function and also promote 
ectopic follicle formation. One possibility is that ectopic follicle 
formation requires expression of PDPN primarily on stromal cells 
and/or APCs rather than on T cells. Another possibility is that these 
two divergent effector functions of PDPN may depend on different 
ligands that PDPN+ T cells interact with during an immune reac-
tion. Thus, one could hypothesize that interaction with one ligand 
mediates T cell inhibition, while interaction with another ligand 
promotes eLF formation. Here, it is important to note that we pre-
dominantly observed eLF formation only after adoptive transfer 
of Th17 cells, but not in active EAE in which a mixture of Th1 and 
Th17 cells is present in the CNS. Thus, pure Th17 cells seem to cre-
ate a special tissue microenvironment conducive to eLF formation, 
and, consequently, different ligands may be expressed in “Th17-
adoptive-transfer-EAE” compared with “active EAE.” PDPN has 3 
known ligands: CLEC-2 (22), galectin-8 (23), and the chemokine 
CCL21 (24). Expression of CLEC-2 is largely restricted to hemato-
poietic cells, including platelets, DCs (25), and B cells (26). We 
at the peak of disease by quantitative PCR (Figure 6C). Analogous 
to our NanoString analysis, both BCL2 and IL-7Rα were reduced 
in natural PDPN+ effector CD4 T cells. Furthermore, we analyzed 
natural PDPN+ and PDPN– effector CD4 T cells isolated from the 
CNS at the peak of disease for expression of the inhibitory mol-
ecules TIM-3 and PD-1 on the cell surface. Consistent with the 
NanoString data, the frequency of TIM-3+PD-1+ double-positive 
cells was significantly increased in PDPN+ effector CD4 T cells 
compared with PDPN– effector CD4 T cells (Figure 6D).
Overall, these data show that natural PDPN+ effector CD4 T 
cells in inflamed tissues preferentially coexpress other inhibitory 
receptors and downregulate prosurvival factors including IL-7Rα, 
indicating that naturally occurring PDPN+ T effector cells have simi-
lar features as PdpnTG T effector cells, may be more easily regulated 
and relatively short-lived, and thereby limit tissue inflammation.
We and others have described previously that Th17 cells come 
in different flavors (17). Thus, Th17 cells generated in the presence 
of IL-6 and TGF-β (without IL-23) are not pathogenic and fail 
to induce EAE upon adoptive transfer. On the other hand, Th17 
cells generated in the presence of IL-1β, IL-6, and IL-23 are highly 
pathogenic and cause severe tissue inflammation upon adoptive 
transfer. Given that PDPN may serve to limit long-term survival 
and/or effector functions of T cells in the target organ, we hypothe-
sized that Th17 cells may express PDPN to curb their own pathoge-
nicity. To test this hypothesis, we determined expression of PDPN 
on Th17 cells generated by IL-6 and TGF-β compared with those 
generated by IL-1β, IL-6, and IL-23. Intriguingly, we found high 
PDPN expression on “nonpathogenic” Th17 cells, whereas “patho-
genic” Th17 cells expressed only very little PDPN (Figure 6E). 
Since PDPN is coexpressed with other inhibitory cell surface 
receptors (TIM-3, PD-1) on T cells in the CNS, our studies suggest 
that PDPN is used to limit survival and quench pathogenicity of 
autoreactive effector T cells and thus inhibit autoimmunity.
Discussion
The data presented here indicate that expression of PDPN on T 
cells may limit the persistence of aggressive T effector cells in the 
target organ. Thus, we have shown that lack of PDPN leads to exag-
gerated T cell responses, as suggested by inflammatory infiltrates in 
multiple organs in globally PDPN-deficient mice, development of 
spontaneous EAE in PDPN-deficient mice on the 2D2 background, 
and exacerbated EAE with increased accumulation of CD4 effector 
T cells in the CNS of T cell–specific PdpnKO mice (Figure 1, Table 
1, and Figure 5). In contrast, PdpnTG mice showed severe periph-
eral lymphopenia and a reduced number of effector T cells in the 
CNS during EAE, resulting in accelerated recovery (Figures 2 and 
4). These data are similar to many observations made with other T 
cell inhibitory receptors (reviewed in ref. 2). For example, CTLA-4–
deficient mice develop multiorgan autoimmunity (10), TIGIT-de-
ficient mice crossed to the 2D2 background develop spontaneous 
EAE (18), and TIM-3 transgenic mice have hypoproliferative T cells 
and develop attenuated EAE (19). These parallels indicate that 
PDPN may also play a role in inhibiting T cell responses.
We describe here that both, in PdpnTG T cells and in natu-
rally occurring PDPN+ T cells in the CNS, expression of PDPN and 
IL-7Rα are inversely correlated, suggesting that PDPN may inhibit 
T cell responses by reducing responsiveness to IL-7 survival sig-
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vided by Maria Ramirez (Boston University, Boston, Massachusetts, 
USA) and crossed with C57BL/6 and 2D2 mice in house. For the gener-
ation of PdpnTG mice, the cDNA of PDPN (C57BL/6 strain) was cloned 
into the human CD2 expression cassette (Supplemental Figure 2 and 
ref. 36). The construct was microinjected directly into C57BL/6 oocytes, 
yielding 3 independent founders: line 552, line 556, and line 560. Pdpnfl/fl 
mice were generated at Taconic Artemis by insertion of loxP sites flank-
ing exon 3 of the PDPN allele using standard methods and backcrossed 
to C57BL/6J mice for more than 6 generations at the University of Bir-
mingham and then bred in house. Pdpnfl/fl mice were crossed with Cd4-
Cre mice and 2D2 mice in house. Clec2–/– mice on 129Sv background 
were provided by Shannon Turley (Dana-Farber Cancer Institute, Bos-
ton, Massachusetts, USA) and crossed with PdpnTG mice (line 560) in 
house. All mice were housed in a specific pathogen–free viral antibody-
free animal facility at the Harvard Institutes of Medicine.
Induction and assessment of EAE. PdpnTG mice (552), WT mice, 
Pdpnfl/fl Cd4-Cre mice, Pdpnfl/fl mice, and Foxp3.GFP KI mice were 
injected s.c. with 100 μg MOG35–55 peptide emulsified in CFA (Difco), 
which was supplemented with 4 mg/ml Mycobacterium tuberculosis 
H37 RA (Difco). Mice also received 100 ng pertussis toxin (List Biolog-
ical Laboratories Inc.) i.v. on days 0 and 2 after immunization. Animals 
were monitored daily for the development of signs of EAE according 
to the following criteria: 0, no disease; 1, decreased tail tone or mild 
balance defects; 2, hind limb weakness, partial paralysis, or severe 
balance defects that cause spontaneous falling over; 3, complete hind 
limb paralysis or very severe balance defects that prevent walking; 4, 
front and hind limb paralysis or inability to move body weight into a 
different position; 5, moribund state.
Isolation of cells from the CNS. WT, PdpnTG, and Foxp3.GFP KI mice 
were sacrificed at the peak of disease and perfused through the left car-
diac ventricle with PBS. Brains and spinal cords were cut into pieces and 
digested for 30 minutes at 37°C with Collagenase D (Roche) at a con-
centration of 2.5 mg/ml and Deoxyribonuclease I (Sigma-Aldrich) at a 
concentration of 1 mg/ml. To prepare a single cell suspension, the tissues 
were mashed and passed through a 70-μm mesh. Mononuclear cells 
were isolated over a 37%/70% Percoll gradient (GE healthcare). Cells 
were either directly analyzed for expression of surface molecules by flow 
cytometry or cells were stimulated for 3 hours with 50 ng/ml phorbol 
12-myristate 13-acetate (Sigma-Aldrich) and 1 μM ionomycin (Sigma- 
Aldrich) in the presence of monensin (GolgiStop, BD Pharmingen). Cells 
were then fixed with 0.4% paraformaldehyde (Electron Microscopy Sci-
ences) and permeabilized with PBS containing 2% FCS and 0.1% Sapo-
nin (Sigma-Aldrich). Cells were analyzed for the production of cytokines 
by staining with anticytokine antibodies and subsequent flow cytometry.
Antibodies and flow cytometry. The following antibodies were used 
for flow cytometry: αCD4 (RM4-5), αCD8 (53-6.7), αCD25 (PC61), 
αCD62L (MEL-14), αCD44 (IM7), αCD11b (M1/70), αCD11c (N418), 
αCD19 (6D5), αNK1.1 (PK136), αCD45.1 (A20), αCD45.2 (104), 
αCD90.1 (OX-7), αCD90.2 (30-H12), αIFN-γ (XMG1.2), αIL-17A (TC11-
18H10.1), αIL-10 (JES5-10E3), αTIM-3 (8B.2C12), αPD1 (RMPI-30), 
αIL-7Rα (A7R34), αPDPN (8.1.1), isotype control Syrian hamster IgG 
(SHG-1), rat IgG2a isotype control (RTK2758), mouse IgG1 isotype con-
trol (MOPC-21), and αVβ11 (KT11) were all purchased from BioLegend. 
αFOXP3 (FJK-16s) and α-γδ-TCR (eBioGL3) were purchased from eBio-
science. αCD3 (1452C11) and 7AAD were purchased from BD Pharmin-
gen. All flow cytometry data were acquired on a BD FACSCalibur or BD 
LSRII and analyzed with FlowJo Tree Star software.
have shown here that the T cell lymphopenia and reduction in 
IL-7Rα levels seen in PdpnTG mice is dependent upon CLEC-2 
(Supplemental Figure 7). Based on this information, it is tempting 
to speculate that the interaction of PDPN+ T cells with CLEC-2+ 
cells might lead to T cell inhibition. However, we cannot exclude 
the possibility that galectin-8, a tandem-repeat type lectin, which is 
ubiquitously expressed by both hematopoietic and nonhematopoi-
etic cells, may also play a role in PDPN-mediated T cell inhibition, 
particularly since several other galectin family members have been 
associated with T cell inhibition (23, 27). Finally, the chemokine 
CCL21 is critical for organizing lymph node structure and poten-
tially also ectopic lymphoid structures, as it guides dendritic cells 
and lymphocytes toward the T cell zone (28). Thus, it is possible 
that, in an acute inflammatory setting, PDPN+ CD4 effector T cells 
will be eliminated quickly due to binding to the inhibitory ligand, 
whereas in chronic inflammatory scenarios, PDPN+ T cells may 
bind CCL21, thereby avoiding the inhibitory interaction, promot-
ing formation of ectopic follicles, and propagating chronic inflam-
mation. In this context, it is interesting to note that formation of 
eLFs typically occurs in chronic diseases, including autoimmune 
diseases like MS, rheumatoid arthritis, and myasthenia gravis, and 
chronic infections, for example, with Borrelia burgdorferi, but not in 
acute infections that resolve quickly (29). Importantly, these seem-
ingly contradictory effects and functions of PDPN are reminiscent 
of another inhibitory T cell receptor, PD-1: although PD-1 strongly 
inhibits T cell responses and promotes tissue tolerance (reviewed 
in ref. 30), it is also expressed on follicular T helper cells in the 
lymph nodes and promotes germinal center reactions (31).
Although PDPN is specifically expressed on Th17 cells in vitro, 
during EAE we detected PDPN expression on both IL-17+ and IL-17– 
T cells in the CNS. However, considering that cell fate mapping 
studies in IL-17ACre mice showed that the vast majority of CNS-in-
filtrating T cells are Th17 or “ex-Th17” cells, producing either IL-17 
or IFN-γ or both (32), it is possible that even PDPN+IL-17–IFN-γ+ T 
cells in the CNS are actually “ex-Th17” cells. Even though PDPN 
may not be exclusively expressed on Th17 cells in vivo, we spec-
ulate that expression of PDPN serves to primarily shut off Th17 
responses. As highly proinflammatory T cells, Th17 cells have the 
potential to cause irreversible tissue damage and therefore need 
to be tightly regulated. Intriguingly, a recent report showed that 
expression of IL-7Rα is essential for maintenance and expansion 
of Th17 responses during EAE (33). In addition, IL-7Rα expression 
is increased on highly pathogenic Th17 cells (34), whereas PDPN 
is more highly expressed on “nonpathogenic” Th17 cells in vitro 
(Figure 6E), supporting the hypothesis that Th17 cells may express 
PDPN to curb their own pathogenicity.
In conclusion, the data presented here show that expression of 
PDPN on T cells can limit survival and accumulation of T effector 
cells in the target tissue. We propose that, after acute inflamma-
tion, PDPN on T cells serves primarily to control long-term Th17 
responses in the target organ by reducing sensitivity to IL-7 sur-
vival signals, thereby preventing tissue damage.
Methods
Mice. C57BL/6, Ly5.1, and Cd4-Cre mice were obtained from The Jack-
son Laboratory. 2D2 mice (12) and Foxp3.GFP-KI mice (35) have been 
described previously. Pdpn–/– mice on 129Sv background (8) were pro-
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background correction was done by subtracting the mean + 2 standard 
deviations of 8 negative control counts (provided by manufacturer) 
and eliminating data that were <1.
RNA isolation and quantitative PCR. RNA was extracted from 
sorted cells using the RNeasy Kit (Qiagen) according to the manu-
facturer’s instructions. RNA was then transcribed into cDNA using 
the iScript cDNA Synthesis Kit (Bio-Rad) according to the manu-
facturer’s instructions. Quantitative PCR primers and probes were 
purchased from Applied Biosystems (BCL2: Mm00477631_m1, 
IL-7R: Mm00434295_m1, PDPN: Mm00494716_m1, TIM-3: 
Mm00454540_m1, PD-1: Mm01285676_m1, β-Actin: 4352341E).
Statistics. All values are expressed as the average ± SEM. Data 
sets were analyzed with the aid of GraphPad Prism Software, ver-
sion 6 (GraphPad). Differences between groups were assessed with 
either 2-tailed Student’s t tests or, in the case of multiple groups, 1-way 
ANOVA with Tukey’s multiple comparison test. P values of less than 
0.05 were considered to be significant. Linear regression analysis of 
EAE data was performed using GraphPad Prism Software.
Study approval. Breeding and experiments were reviewed and 
approved by the Institutional Animal Care and Use Committee of Har-
vard Medical School.
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Histopathologic analysis. Lung, liver, small and large intestine, 
CNS, and heart tissues were harvested from Pdpn–/– mice and their 
WT or heterozygous littermates. Tissues were fixed in 10% neutral 
buffered formalin and processed routinely for paraffin embedment. 
Slides were stained with hematoxylin and eosin stains. For identi-
fication of T cells by immunohistochemistry, standard avidin-bio-
tin staining was performed on the sections with rabbit anti-mouse 
CD3g (Abcam), using reagents from Vector Laboratories. Normal 
mouse spleen tissue served as positive staining controls; negative 
controls included omission of the primary antibody. To quantify 
infiltrates in the small intestine, 2 different sections of eight to nine 
1-cm pieces of small intestine were evaluated for each mouse for 
presence and number of small (10–20 small, round, dark-blue cells 
in diameter), medium (20–40 cells in diameter), and large (>40 
cells in diameter) infiltrates.
For analysis of CNS inflammation in EAE, mice were sacrificed 30 
days after immunization or in case of spontaneous disease after ani-
mals reached a stable score. Brains and spinal cords from 2D2 Pdpn–/– 
mice and 2D2 Pdpn+/– littermates and from PdpnTG mice (line 552) and 
their WT littermates were fixed in 10% neutral buffered formalin and 
processed routinely for paraffin embedment. Slides were stained with 
Luxol fast blue-hematoxylin and eosin stains. Inflammatory foci (>10 
mononuclear cells) were counted in leptomeninges and parenchyma 
in a blinded fashion in that the pathologist was unaware of the clinical 
status and genotype of the mice.
NanoString gene expression analysis. Foxp3.GFP-KI mice were 
immunized with MOG/CFA for the development of EAE. At the peak 
of disease, infiltrating cells were isolated from the CNS and Foxp3.
GFP–CD11b–CD4+PDPN+ and Foxp3.GFP–CD11b–CD4+PDPN– T effec-
tor cells were isolated by FACS sorting. Cells were then immediately 
lysed using RLT buffer (Qiagen). Cell lysates were hybridized with 
a custom-made CodeSet according to the manufacturer’s instruc-
tions. Barcodes were counted (1,150 fields of view per sample) on 
an nCounter Digital Analyzer following the manufacturer’s protocol 
(NanoString Technologies Inc.). Data were processed using nSolver 
Analysis Software first by normalization with respect to the geometric 
mean of the positive control spike counts (provided by manufacturer) 
and then with 4 reference genes (Actb, Gapdh, Hprt, and Tubb5). A 
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